Our CFO, Lauren White, joins Boston Business Journal “Biotech’s Future – Innovation, AI and our Competitive Edge” panel this Thursday with other industry leaders to discuss the future of biotech & life sciences in MA. Don’t miss this dynamic discussion! bit.ly/44VDFLK

We're featured in Nature Biotechnology's “Editor’s Pick” for our work developing #neuropsychiatric medicines using our proprietary Glyph platform. Read about how we're advancing novel therapies with clinically validated mechanisms for depression & anxiety: bit.ly/47f4jke

Our CEO Daphne Zohar joined Brad Loncar & Kendalle Burlin O'Connell on BiotechTV's Biotech Direct to discuss policy & regulatory issues, funding, FDA changes, transparency, & boosting US drug development. Watch for insights including a policy change “wish list.”

This summer, the team had a blast together building meaningful connections. From everyday moments to unique outings, these experiences reinforce our bonds & remind us of our shared mission to serve those with #MentalHealth conditions like #depression & #anxiety. Excited for more!

Congrats to COBENFY & ZURZUVAE teams for 2025 #PrixGalien Best Pharmaceutical Product noms! Kudos to all involved (@PureTechh, Karuna for COBENFY) in the successful journeys, notably Seaport's Dr. Steve Paul for his role in advancing both nominated drugs bit.ly/3V6cx72

Dan Bonner, Co-Founder & SVP, Platform at Seaport will present at the Neuropsychiatric Drug Development Summit in Boston on 9/11 at 1:30pm to share insights on the discovery & selection of novel lymphatic-targeted prodrug candidates using clinical evidence ter.li/42ap36

Pleased to share the first participant has been dosed in our Ph1 study of GlyphAgo™ (SPT-320). This is our 2nd therapeutic candidate in clinical development & represents an important clinical advancement for patients w/GAD. bit.ly/4meQFl0

Looking forward to two upcoming investor conferences: 1x1s & company presentation at Oppenheimer & Co. Inc.'s Private Life Sciences Company Showcase on 9/25 at 11:45am ET & 1x1s at the 5th Annual Needham Private Biotech & MedTech Company Forum, held 10/14-10/15. bit.ly/42z6Fr1

We’re a FierceBiotech Fierce 15 winner! Our Glyph platform, proven team, & focus on validated mechanisms put us among the most “innovative & visionary” companies as we advance clinical programs aiming to deliver new medicines for #depression & #anxiety. bit.ly/4msojnm

Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer & Co. Inc. Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/

Biotech founders are often patient advocates, inspired by family members to develop life-changing medicines. We’re also small businesses. Mass biotech drove 17% of all job growth in 2024, $23B in annual wages, and 1,000+ companies. But our industry is misunderstood & maligned. We

We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below some takeaways

Members of our exec team joined FierceBiotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7

Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.

At the #StatusList dinner last night I was asked what I would change about our industry. My response: the likelihood of making it from discovery to FDA approval is ~1% & takes 10-15 yrs yet the incentives focus only on rewarding the successes w/ so much waste & lost knowledge. We

“We Own It” is a core value of ours & captures our entrepreneurial spirit. Co-Founder & CEO, @DaphneZohar, shows us how it's done. Named a Goldman Sachs Most Exceptional Entrepreneur, she inspires us to push boundaries so we can best serve those with #neuropsychiatric conditions.

Co-Founder & CEO, Daphne Zohar joined an all-women Rare & Neuro Diseases panel at #USAIC25 (watch: bit.ly/3LcJkWg) & gave a shoutout to the Biotech CEO Sisterhood in her opening remarks (view: bit.ly/3X1WPKY). Join us at #USAIC26: bit.ly/4oEvmei

Happy Halloween! We had so much fun celebrating together w/ themed team costumes & plenty of laughs. These gatherings remind us how connection energizes our shared commitment to developing new medicines for people living w/ #neuropsychiatric conditions like #depression & #anxiety

Members of our management team will present at the Stifel 2025 Healthcare Conference on November 11 at 10:00AM ET. The team will also participate in 1x1 meetings during the conference. Press release: bit.ly/49x28cP Live & archived webcast here: seaporttx.com/news-papers/

Tune in today at 10:00AM EST as our CFO, Lauren White, & CSO, Michael Chen, present at the Stifel 2025 Healthcare Conference. The team will also participate in 1x1 meetings while at the conference. Tune in: bit.ly/4oNTUBA Replay available here: bit.ly/43Nvu33